| Issue Date |
Title |
Author(s) |
| 15-Nov-2022 |
A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China |
Jiang, Qian;Li, Zongru;Qin, Ya-Zhen;Zhao, Ting;Liu, Bingcheng;Chen, Zi;Niu, Qian;Men, Lichuang;Wang, Hengbang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
| 2018 |
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma |
Yi, Hanjie;Yan, Xianglei;Luo, Qiuyun;Yuan, Luping;Li, Baoxia;Pan, Wentao;Zhang, Lin;Chen, Haibo;Wang, Jing;Zhang, Yubin;Zhai, Yifan;Qiu, Miao-Zhen;Yang, Da-Jun |
| 18-Aug-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 31-Oct-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 20-Feb-2023 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 2018 |
Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study |
Jiang, Qian;Huang, Xiao Jun;Chen, Zi;Men, Lichuang;Liu, Wei;Sun, Xuemei;Ji, Jiao;Wang, Hengbang;Hou, Yue;Hu, Po;Zou, Lei;Yan, Hua;Huang, Yingjie;Yang, Dajun;Zhai, Yifan |
| 23-Nov-2021 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Song, Yongping;Zhang, Gongli;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yujun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 15-Nov-2022 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation |
Jiang, Qian;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Zhang, Yanli;Song, Yongping;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yu-Jun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
| 23-Nov-2021 |
Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Qin, Yazhen;Zhao, Ting;Liu, Bingcheng;Chen, Zi;Niu, Qian;Men, Lichuang;Wang, Hengbang;Yang, Dajun;Zhai, Yifan;Huan, Xiaojun |
